Table 1.

Characteristics included in the ACA questionnaire

Characteristics	Estimates
Remission	45 out of 100 patients go into remission 25 out of 100 patients go into remission 15 out of 100 patients go into remission
Improvement	70 out of 100 patients feel much better, but occasionally have some joint pain or swelling 50 out of 100 patients feel much better, but occasionally have some joint pain or swelling 40 out of 100 patients feel much better, but occasionally have some joint pain or swelling
Radiographic progression	No further bone damage seen on X-rays in 80 out of 100 patients No further bone damage seen on X-rays in 50 out of 100 patients No further bone damage seen on X-rays in 30 out of 100 patients
Route	Pill you take once a week Injection you give yourself once every 1–2 weeks Intravenous infusion you get every 6–8 weeks
Injection reaction	No injection reactions 30 in 100 patients get a rash or local burning at the site of injection 3 in 100 patients will get a reaction during the infusion (headache, nausea, fever)
Reversible adverse events	No increased risk of nausea, dizziness or unusual tiredness 10 in 100 people will have nausea, dizziness or unusual tiredness
Risk of lung injury	No increased risk of lung or liver injury Rare risk of lung injury (2 in 100 patients) or liver injury (about 1 in 1000 patients)
Risk of tuberculosis	No increased risk of tuberculosis Extremely rare risk of tuberculosis (about 1 in 10,000 patients)
Extremely rare adverse events	No increased risk of neurologic disease or heart failure. Extremely rare risk of neurologic disease or heart failure (about 1 in 10,000 patients)
Risk of cancer	No increased risk of cancer Possible increased risk of cancer (about 1 in 1000 patients)